The metabolic fate of L-histidine, summarized in Fig. 1 , has been the subject of renewed interest because of the realization that some stages of its breakdown to glutamic acid are folate dependent (Bakerman, Silverman,
, and that the intermediates of this metabolic pathway are readily accessible for examination in the urine.
In the absence of a competent folic acid coenzyme to act as an acceptor for the formimino group, formiminoglutamic acid (Figlu, Fig. 2 (Luhby and Cooperman, 1964) .
We have recently reported the use of ascending chromatography on thin layers of cellulose as a relatively simple, sensitive, and rapid method for simultaneous separation and semi-quantitative estimation of Figlu and urocanic acid (Mohamed and Roberts, 1964; Roberts and Mohamed, 1965) . The method has now been used to estimate the urinary excretion of these two metabolites on histidine loading in a representative group of cases and the results have been examined to assess the claim of Bennett and Chanarin in respect of urocanic acid.
PATIENTS, MATERIALS, AND METHODS

PATIENTS
The 64 subjects studied are listed in Table I .
The 15 control subjects were eight healthy adult members of the staff, and seven patients, who had no evidence of any gastrointestinal or haematological abnormality or conditions likely to produce folate deficiency.
All five patients with the malabsorption syndrome were anaemic with a 'dimorphic' peripheral blood picture, but only three showed megaloblastic erythropoiesis. Three patients had a histamine-fast achlorhydria. In two of these, and in one patient with free acid, a jejunal biopsy was performed, and this showed partial or subtotal villous atrophy. All five patients showed flat glucose tolerance curves, subnormal excretion of D-xylose, and a flocculation pattern on x-ray examination of the small intestine, but only four had frank steatorrhoea. The fat excretion in the remaining patient averaged 4-8 g./day. Of the four patients in whom it was tested, vitamin B12 absorption was subnormal in two but was not in the range characteristic of pernicious anaemia. In only one of these could it be corrected by the administration of hog intrinsic factor. A complete haematological response to folic acid was obtained in four of the five patients after an initial suboptimal response to vitamin B12. The remaining patient, showing a mild dimorphic anaemia with normoblastic erythropoiesis, responded to a gluten-free diet alone.
All six patients with pernicious anaemia were previously untreated cases who had megaloblastic anaemia, histamine-fast achlorhydria, and a defect of vitamin B12 absorption which could be corrected by giving hog intrinsic factor. A classical response to vitamin B12 therapy occurred in each case.
The patient with Crohn's disease was a young woman of 24 with moderate hypochromic, normoblastic anaemia, a flat glucose tolerance curve, and malabsorption of D-xylose and fat. She had radiological evidence of regional ileitis involving the terminal ileum. An 18-inch portion of the diseased bowel was subsequently resected.
The 17 patients with partial gastrectomy all had had a Polya repair five or more years earlier and none was anaemic at the time of the test.
Cirrhosis of the liver in both patients was of the cryptogenic variety, and both had liver cell failure, with moderate normochromic anaemia, leucopenia, and thrombocytopenia. The patient with cardiac failure was a woman of 84 with valvular heart disease and moderate iron-deficiency anaemia.
Of the nine patients with thryotoxicosis, two had associated diseases; one, a boy of 15, had an iron-deficiency anaemia with splenomegaly, and he responded well after treatment with iron; and the other was a man of 54 who had undergone a mitral valvotomy 18 months earlier and had subsequently remained free of congestive failure, auricular fibrillation being controlled with digitalis. (Roberts and Mohamed, 1965) , also showed a megaloblastic anaemia with defect of vitamin B12 absorption of the type found in pernicious anemia.
TEST tJRNNES These were collected over an eight-hour period after a loading dose of 15 g. of L-histidine monohydrochloride. Aliquots of the measured total volume were stored at -20°C. until the time of the assay.
ESTIMATION OF FIGLU AND UROCANIC ACID This was
carried out by the semi-quantitative method on thin-layer chromatograms, as described previously (Mohamed and Roberts, 1964; Roberts and Mohamed, 1965) .
RESULTS
The eight-hour excretions of Figlu and urocanic acid in 24 tests in the 15 control subjects are shown individually in Figure 3 . The mean combined excretion of the two metabolities was 13-8 mg. and the mean + 2-32 standard deviation level, i.e., the level which would be expected to be exceeded by a normal subject once in 100 tests, was 38-6 mg., or approximately 40 mg. Using the 40 mg. level for the combined excretion as the discriminant, it can be seen in Table I that excretions in excess of this were found in all five patients with the malabsorption syndrome, in two of the six patients with pernicious anaemia, in the one patient with Crohn's disease, and in three of the 17 patients who had had a Polya gastrectomy. Both the patients with cirrhosis of the liver exceeded this figure, as did the one patient with cardiac failure, six of the nine thyrotoxic patients, and six of the eight patients with the various malignant diseases. (27-0%) (4322%) (6) 6 Crohn's disease (Chanarin, 1960; Carter, Heller, Schaffner, and Korn, 1961; Herbert and Zalusky, 1962; Knowles and Prankerd, 1962; Chanarin, Bennett, and Berry, 1962; Luhby and Cooperman, 1964; Kershaw and Girdwood, 1964) . The abnormal results in three of the 17 patients who had a Polya gastrectomy are comparable with the 10-4 % incidence of folate deficiency, as assessed by bio-assay of serum folate activity (Deller, Ibbotson, and Crompton, 1964) . These cases will be described in detail elsewhere.
Interference with folate metabolism, or a relative deficiency because of increased utilization, as assessed by increased urinary excretion of Figlu, subnormal urinary excretion of an oral dose of folic acid, rapid plasma clearance of an intravenous dose of folic acid, dscreased liver content of folate, or even the presence of megaloblastic anaemia, have been described in malignant disease (Ehrlich and Lazarus, 1900; Swendseid, Swanson, Meyers, and Bethell, 1952; Girdwood, 1953; 1959; Broquist, 1956; Chanarin, Mollin, and Anderson, 1958; Chanarin et al., 1962; Romine, 1960; Chanarin, 1963; Villamil and McCracken, 1963; Karlin, 1963; Carey, Brena, and Krant, 1964; Kershaw and Girdwood, 1964; Dymock, 1964) . Increased levels of Figlu and/or urocanic acid have been noted in cirrhosis of the liver (Luhby et al., 1959a; Carter, Schaffner, and Heller, 1960; Carter et al., 1961; Merritt, Rucknagel Silverman, and Gardiner, 1962; Knowles, Shaldon, and Fleming, 1963; Villamil and McCracken, 1963; Kershaw and Girdwood, 1964) (Daly and Rose, 1964) .
The abnormal results in six of the nine thyrotoxic patients, without significant complicating diseases, are of interest and these cases have been reported (Mohamed and Roberts, 1965) . Theoretically, there are several ways in which thyrotoxicosis may interfere with folate metabolism: an increased requirement for folate consequent upon the general enhancement of metabolism or the known increase in red cell mass (Muldowney, Crooks, and Wayne, 1957) could account for it. The possibility of liver cell dysfunction in thyrotoxicosis (Cameron and Karunaratne, 1935; Maddock, Coller, and Pedersen, 1936; Shaffer, 1940; McIver and Winter, 1943; Piper and Poulsen, 1947; Myers, Brannon, and Holland, 1950; Movitt, Gerstl, and Davis, 1953) 
